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Types of Cardiomyocyte
Death and Clinical Outcomes
in Patients With Heart Failure*
Sawa Kostin, MD, PHD
Bad Nauheim, Germany
Despite all efforts in pharmaceutical treatment, heart
failure is still a major cause of morbidity and mortality
worldwide (1). The fundamental mechanism that under-
lies the progressive nature of myocardial dysfunction
leading to heart failure has been termed remodeling. As
defined by Cohn et al. (2), this process consists of a
complex of molecular and cellular events that lead to
important changes in the structure, function, and pheno-
type of the myocardium.
See page 1523
Until recently, single myocyte cell loss scattered dif-
fusely throughout the ventricle was largely ignored as a
potential pathogenetic factor in failing myocardium.
However, it has now widely been recognized, and there is
general consensus that replacement fibrosis is the conse-
quence of the reparative process following myocyte cell
loss (3–5). The lack of knowledge of myocyte cell death
as a pathogenetic factor of heart failure was due to the
general belief that cell necrosis following acute myocar-
dial ischemia was the exclusive mechanism of myocyte
death in the myocardium (6), because of a lack of
evidence and of methodological approaches to detect the
occurrence of single cell death.
During the past decade, a number of different meth-
ods, including electron microscopy, as well as molecular
and immunohistochemical approaches, have demon-
strated that myocyte cell death can be identified, and this
has generated the consensus that the magnitude of its
occurrence is a quantifiable parameter in the normal and
the pathological heart (Table 1). Majno and Joris (7)
distinctly defined the different types of cell death. Fol-
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that he has no relationships to disclose.lowing their nomenclature, the Society of Toxicologic
Pathology recommends that the term necrosis be reserved
or the changes that occur after cell death, regardless of
he pathway by which the cells die (8). The modifiers
apoptotic” and “oncotic” should be used to specify the
redominant cell death pathway. This opinion is increas-
ngly shared by many researchers (7,9 –11). In addition to
poptosis (programmed cell death type I) and oncosis,
ccumulating evidence indicates the occurrence of a third
ode of cell death (programmed cell death type II),
amely, autophagic cell death (7,12–20). Thus, the rec-
gnition that cardiac myocytes die by multiple mecha-
isms and therefore substantially affect ventricular re-
odeling in diseased human hearts supports the concept
f ongoing myocyte death in the progression of heart
ailure (3,15,21–23). It is worthy to note that the nomen-
lature of the 3 major types of cell death, namely, apoptotic,
ncotic, and autophagic cell death, is the one most fre-
uently used in the literature.
Autophagic cell death is a morphologic term derived from
lectron microscopic observations that denotes a form of cell
eath in which abundant autophagic vacuoles are present in
he cytoplasm. Autophagy is referred to as an intracellular
ysosome-mediated catabolic metabolism that is responsible
or the bulk degradation and recycling of damaged or
ysfunctional cytoplasmic components and intracellular or-
anelles (24). Although autophagy plays an important role
n cellular homeostasis, excessive autophagy might be ex-
ected to cause cellular destruction if the process is carried
eyond a certain threshold. As a consequence, the cell
cannibalizes itself” from inside. Over time, this would
ean that a significant percent of cytoplasm is being
emoved in an indiscriminate manner, resulting in negative
ffects on cell survival. Autophagy is associated with a
rowing number of pathological conditions, including can-
er, neurodegenerative disorders, myopathies, and cardio-
yopathies (9). Numerous studies have demonstrated that
he proteasomal, autophagic, and lysosomal proteolytic
athways share cross-talk communication, and the impair-
ent of each of these systems may lead to cellular degen-
ration and cell death (9,15).
It should be mentioned that a mixed type of myocyte cell
eath may also occur, namely, “autophagic necrosis,” which
efers to a mode of cell death that combines morphological
eatures of autophagy and necrosis, which is a result of the
ailure of the compensatory, prosurvival autophagic response
19). Similarly, the degree of adenosine triphosphate deple-
ion (25) and the rate of mitochondrial permeability tran-
ition pore formation (26) could drive a cell toward apopto-
is or necrosis or even change 1 morphology to another (i.e.,
necroptosis”) (27).
From previous studies in patients with heart failure due
o dilated cardiomyopathy, severe aortic valve stenosis, or
ibernating myocardium, a total annual loss of more than
0% of cardiomyocytes is predicted (Table 2). What has
micro
d
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dropout correlates with clinical outcomes.
In this issue of the Journal, Vigliano et al. (28)
elegantly demonstrate for the first time that cardiomyo-
cyte hypertrophy and cell damage by autophagic degen-
eration and death, especially when associated with onco-
sis, are independent predictors of death in patients with
dilated cardiomyopathy and advanced heart failure. The
investigators used most of the well-established markers
for cell death (Table 1).
From this study (28) and previous studies (15,22,29),
albeit indirectly, it is suggested that another variable of the
progression of contractile dysfunction to terminal heart
failure is the imbalance between myocyte cell death and
myocyte renewal. For this reason, preventing myocyte cell
death and an increasing generation of new myocytes may
represent attractive targets in the treatment of human heart
failure. Tremendous work to study the biology of either
resident or circulating stem or pluripotent cells in myocar-
dial regeneration still remains (30–32). Prospective clues to
enhance myocardial regeneration are the newly discovered
cells termed telocytes (33,34), formerly called myocardial
interstitial Cajal-like cells (35), which are believed to nurse
or “guide” the endogenous and exogenous stem cells for
activation and commitment, but they also act as support-
ing cells for progenitor cells migration toward injured
myocardium (36).
In conclusion, many more studies are needed to under-
stand the delicate balance between cardiomyocyte death and
cardiomyocyte renewal, thereby improving clinical out-
Diagnostic Techniques for the Detection of the Major Modes of CeTable 1 Diagnostic Techniques for the Detection of the Major
Oncosis A
Electron microscopy Electron microscopy
Pfu polymerase assay (hairpin 2 for oncosis) TUNEL, EM-TUNEL
Intravital dyes (propidium iodide, Evans blue dye) Taq polymerase ass
Uptake of high-molecular proteins (IgG, albumin, dextran) DNA laddering detec
Myocyte enzymes release Nuclear lamina frag
Dystrophin labeling Caspase activation t
Complement 9 labeling Caspase substrate c
Annexin V staining
*Invitrogen Corporation (Carlsbad, California). Reprinted, with permission, from Kostin et al. (15).
DNA  deoxyribonucleic acid; EM  electron microscopy; IgG  immunoglobulin G; LC3 
eoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick end labeling.
Extent of Different Forms ofCardiomyocyt Cell Death in Failing Human HeartsTable 2 Extent of Different Forms ofCardiomyocyte Cell Death in Failing Human Hearts
Type of Cell Death
Detection
Rate
Completion Time for
Cell Removal
Annual Rate of
Myocyte Loss
Apoptotic necrosis 0.002% Several hours 2%–4%
Oncotic necrosis 0.06% 48 h 11%
Autophagic cell death 0.08% Unknown 10%?
Total 20%–25%Reprinted, with permission, from Kostin (9).comes in patients with heart failure, irrespective of its
etiology.
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